ARV-110, an investigational oral therapy that degrades the androgen receptor, has a favorable safety profile and showed promising anti-tumor activity in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC), updated Phase 1 data suggests. The approach worked particularly well in a population with specific mutations in the androgen receptor, the researchers said. But it also was found to have promising efficacy in a group of patients without genetic alterations in the receptor. Arvinas, its…
You must be logged in to read/download the full post.
The post Oral ARV-110 Shows Promise in Heavily Treated mCRPC Patients appeared first on BioNewsFeeds.